PeptideDB

(Des-Gly)-Glutathione-monoethyl ester (reduced)

CAS No.: 114627-30-4

(Des-Gly)-Glutathione-monoethyl ester (reduced) also called γ-GCE, GCEE, it has been shown to be much more easily trans
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

CAS 114627-30-4
Sequence H-Glu(Cys-OEt)-OH
Sequence Single E(C-OEt)
Molecular Formula C10H18N2O5S
Molecular Weight 278.33
Synonyms γ-GCE, GCEE
Technology Synthetic
Storage -20°C, avoid light, cool and dry place
Application Alzheimer’s Disease|Di- and Tripeptides
Description (Des-Gly)-Glutathione-monoethyl ester (reduced) also called γ-GCE, GCEE, it has been shown to be much more easily transported into isolated rat hepatocytes than glutathione. Within the cells it could be converted into reduced glutathione. Therefore it could - better than glutathione - prevent immunological cell injury in isolated rat hepatocytes treated with anti-rat liver plasma membrane rabbit antiserum. γ-GCE may help to reduce oxidative stress in various biological systems by promoting the biosynthesis of glutathion. For this reason, administration of γ-GCE and N-acetyl-cysteine (NAC) was discussed as a potential therapeutic approach for Alzheimer disease.
References 1.  The core Alzheimer’s peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? H.Han et al., Chemistry and Biology, 2, 163 (1995) 2.  Elevation of glutathione as a therapeutic strategy in Alzheimer disease. C.B.Pocernich and D.A. Butterfield, Biochim. Biophys. Acta, 1822, 625 (2012) 3.  Preventive effect of gamma-glutamylcysteinylethyl ester on immunological cell injury in isolated rat hepatocytes with anti-rat liver plasma membrane antiserum treatment. K.Nishida et al., Res. Commun. Chem. Pathol. Pharmacol., 82, 49 (1993) 4.  Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemobrain. G.Joshi et al., J. Neurosci. Res., 85, 497 (2007)